140652-99-9

JCP-265 is an inhibitor of ABHD6 that works in a dose-dependent manner.

JCP-265 is a compound used for in vivo phenotypic screening of small molecule libraries, which has the activity of screening molecules that regulate cell function. JCP-265 uses molecular cell barcoding technology to directly screen small molecule libraries in vivo for studying complex physiological processes, such as screening compounds related to targets in pancreatic cancer metastasis seeding studies.

[1] An in vivo multiplexed small-molecule screening platform DOI:10.1038/nmeth.3992